Roflumilast, a new orally active phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 374s Year: 2002
Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is safe and well tolerated in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002
A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD Source: Eur Respir J 2009; 33: 1039-1044 Year: 2009
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension Source: Eur Respir J 2008; 32: 198-209 Year: 2008
Cilomilast, a potent, selective inhibitor of phosphodiesterase 4, improves small airway function in patients with chronic obstructive pulmonary disease: results of a 6-month trial Source: Eur Respir J 2001; 18: Suppl. 33, 94s Year: 2001
Beyond corticosteroids: future prospects in the management of inflammation in COPD Source: Eur Respir Rev 2011; 20: 175-182 Year: 2011
Physiological effects of roflumilast at rest and during exercise in COPD Source: Eur Respir J 2012; 39: 1104-1112 Year: 2012
Experience of application the selective phosphodiesterase-4 inhibitor roflumilast in the patient with COPD and the metabolic syndrome Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016
Effect of phosphodiesterase 4B inhibitor GSK256066 on leukocyte/endothelium interactions from chronic obstructive pulmonary disease: an in vitro study. Source: International Congress 2017 – Management of COPD Year: 2017
PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013
Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015
The use of combination therapy in pulmonary arterial hypertension: new developments Source: Eur Respir Rev 2009; 18: 148-153 Year: 2009
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019
Combined inhalation of iloprost and the dual selective phosphodiesterase (PDE) inhibitor tolafentrine in a model of acute pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001
Adenosine 5’ – triphosphate (ATP) and adenosine 5' – monophosphate (AMP) challenge testing in current smokers and patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 414s Year: 2003
Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension? Source: Eur Respir Rev 2009; 19: 68-71 Year: 2010
RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016
The novel selective PDE4 inhibitor roflumilast: early onset of efficacy in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014